ELAB

NEWPORT BEACH, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company"), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the "Quarterly Report") for the three and six months ended June 30, 2026, with the U.S. Securities and Exchange Commission ("SEC"). The Quarterly Report is available on the SEC's website at www.sec.gov under the Company's filings. Q2 2026 was a quarter of meaningful revenue and balance sheet growth, driven by the Company's operating platform and continued M&A execution, including the closing of the A&B Aerospace, Inc. ("A&B Aerospace") acquisition on May 11, 2026. A&B Aerospace is an AS9100D-certified precision machining and aerospace manufacturing company based in Southern California, serving Tier 1 customers including Boeing, Honeywell, and Moog. A&B Aerospace generated approximately $4.5 million in trailing-twelve-month revenue at closing and is cash-flow positive. Balance Sheet Highlights Total assets increased to approximately $36.6 million as of June 30, 2026, up 40% from approximately $26.0 million at March 31, 2026, up 184% from approximately $12.87 million at year-end 2025, and up 290% year-over-year. Shareholders' equity grew to approximately $17.4 million, up 38% from approximately $12.6 million at March 31, 2026, up 122% from year-end 2025, and up 92% year-over-year. Cash and cash equivalents ended the quarter at approximately $18.1 million, up from approximately $14.4 million at March 31, 2026 and approximately $5.4 million at year-end 2025, representing the largest cash balance in the Company's history. Net working capital improved to approximately $6.2 million, from approximately $5.1 million at March 31, 2026 and approximately $2.9 million at year-end 2025. Revenue Growth Q2 2026 revenue reflects contributions from all four operating manufacturing and packaging subsidiaries, with A&B Aerospace contributing a partial period following its closing on May 11, 2026. Revenue for the three months ended June 30, 2026 was approximately $1.31 million, compared to $nil for the same period in 2025. On a sequential basis, revenue grew approximately 92% from approximately $682,000 in the first quarter of 2026. Revenue for the six months ended June 30, 2026 was approximately $1.99 million, approximately 3.4 times the Company's entire FY2025 revenue of approximately $590,000. Q2 2026 reflects the trajectory the Company has been building toward: a diversified holding company with five acquired operating businesses spanning precision machining and aerospace manufacturing, specialty IT packaging, biosciences, and defense technology, supported by the strongest balance sheet in its history. PMGC believes the industries in which its subsidiaries operate, including the aerospace and defense supply chain and the semiconductor and data infrastructure markets, continue to benefit from durable, long-term demand drivers. The Company intends to continue pursuing strong, durable businesses within its current industries, while also evaluating opportunities in new industries and companies that it believes will be accretive and add long-term value for its shareholders. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact: [email protected]

Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development. NEWPORT BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced positive results from Phase III of its AI-driven drug discovery program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences"). Phase III of the parties’ drug discovery program (“Phase III”) was designed to biologically validate a focused set of small-molecule candidates selected by Yuva Biosciences' proprietary MitoNova™ AI platform. These candidates were tested in primary human skeletal muscle cells using an in vitro assay measuring ANT1 protein expression. ANT1 is a mitochondrial protein involved in cellular energy metabolism in skeletal muscle. The parties’ drug discovery program is focused on identifying candidates that may support the Company's broader development strategy around muscle preservation, including potential applications relevant to muscle health and metabolic stress. The study in Phase III evaluated a focused set of AI-selected small-molecule candidates. According to the results package prepared by Yuva Biosciences, four compounds (C1, C2, C3, and C4) increased ANT1 expression, with the strongest candidates demonstrating dose-dependent induction. Yuva Biosciences’ results report identified C1, C2 and C4 as the strongest and most dose-consistent ANT1 inducers, while C3 also advanced as a candidate based on statistically significant activity at the highest tested dose. Key Phase III Findings Connection to Prior Program Update The Company previously announced that Phase III was expected to use Yuva Biosciences' improved sixth-generation classifier models to support a more refined selection of candidate compounds and a more comprehensive in vitro validation stage. The prior update also stated that Phase III results were expected in Q2 2026. View the prior PMGC press release. Next Steps Based on the positive Phase III results, NorthStrive Biosciences and Yuva Biosciences are evaluating next steps, including confirmatory testing and further development of the four validated candidates. The proposed next stage is expected to evaluate whether the ANT1 induction observed in primary human skeletal muscle cells is maintained in a more mature muscle model that more closely reflects adult skeletal muscle biology. About Yuva Biosciences, Inc. Yuva Biosciences, Inc. is a mitochondrial sciences AI company that uses advanced artificial intelligence to identify and develop therapeutic and natural candidates targeting aging-related pathways. Its proprietary AI platform, MitoNova™, integrates proprietary biological, chemical, and mitochondrial-function datasets to accelerate the discovery of compounds with the potential to improve cellular processes and overall tissue health. Multiple products incorporating compounds discovered by Yuva Biosciences are already on the market, including Revive+ by BosleyMD. Yuva Biosciences is headquartered in Birmingham, Alabama. For more information, please visit www.yuvabio.com. About NorthStrive Biosciences Inc. NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. NorthStrive's lead asset, EL-22, leverages an engineered probiotic approach to address the issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations, the ability to obtain, maintain and enforce patent protection, whether patent applications will issue or claims will be allowed, clinical and regulatory development timelines, potential indications, safety and efficacy, and market opportunity. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential significance of the Phase III results, the potential advancement of candidate compounds, future confirmatory testing, further characterization and development, the potential relevance of ANT1 induction, the Company's muscle preservation strategy, and the potential applications or benefits of the AI-driven drug discovery program. The results described in this press release are based on in vitro testing and are preliminary in nature. The Company cannot provide assurance that any candidate will demonstrate similar activity in future testing, differentiated models, animal studies, clinical studies, or any commercial application. There can be no assurance that the Company or Yuva Biosciences will successfully advance any candidate, complete additional studies, obtain regulatory approvals, develop a product candidate, or generate revenue from this program. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact: [email protected]

NEWPORT BEACH, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company, has filed its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the three months ended March 31, 2026, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the Company’s filings. Q1 2026 was a quarter of meaningful balance sheet growth, driven by the Company’s financing and M&A activities, including the closing of the SVM Machining Inc. (“SVM”) acquisition. SVM is a Northern California-based precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. Balance Sheet Highlights Total assets increased to approximately $26.0 million as of March 31, 2026, up 102% from approximately $12.87 million at year-end 2025 and up 193% year-over-year. Shareholders’ equity grew to approximately $12.6 million, up 61% from approximately $7.84 million at year-end 2025 and up 55% year-over-year. Cash and cash equivalents ended the quarter at approximately $14.4 million, up from $5.4 million at year-end 2025 and representing the largest cash balance in the Company’s history. Net working capital improved to approximately $5.1 million from $2.9 million at year-end 2025. Revenue Growth Q1 2026 revenue reflects the contribution from all three operating manufacturing and packaging subsidiaries, with SVM Machining contributing a partial period following its closing on February 2, 2026. Revenue for the three months ended March 31, 2026 was approximately $682,000, compared to $nil for the same period in 2025. Q1 2026 revenue exceeded the Company’s entire FY2025 revenue of approximately $590,000 in a single quarter. On a sequential basis, revenue grew approximately 124% from approximately $304,000 in the fourth quarter of 2025. Subsequent Events Subsequent to quarter-end, the Company executed several additional strategic initiatives: Formation of NorthStrive Defense Tech LLC (“NorthStrive Defense”) on April 2, 2026, a company that will focus on identifying, acquiring, and commercializing advanced defense technologies, with an emphasis on drone and autonomous systems. Following this formation, NorthStrive Defense signed two agreements with the option to acquire a patented GPS-denied autonomous drone navigation technology and multi-domain drone payload technology designed for air and water operations. Entry into a new $40 million equity purchase facility with an institutional investor on April 17, 2026, with an initial tranche of approximately $10 million funded at closing. The Company may draw additional amounts at its sole discretion over a 24-month commitment period. This facility will provide the Company with committed, flexible capital to continue executing on its active M&A pipeline currently focused on aerospace, defense, and industrial manufacturing. Closing of the acquisition of A&B Aerospace, Inc. (“A&B Aerospace”) on May 12, 2026. A&B Aerospace is a precision machining and aerospace manufacturing company based in California, serving Tier 1 customers, including Boeing, Honeywell, and Moog. A&B generated approximately $4.5 million in trailing-twelve-month revenue and is cash-flow positive. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact: [email protected]

Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 Treatments NEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”). The Annual Report is available on the SEC’s website at www.sec.gov under the Company’s filings and on the Company’s investor relations website. A Year of Capital Allocation and Asset Growth Fiscal 2025 marked a year of disciplined capital deployment and balance sheet expansion. Total assets increased 43%, from approximately $8.99 million in the fiscal year ending December 31, 2024 (“FYE 2024”) to approximately $12.87 million in FYE 2025. Shareholders’ equity increased from approximately $6.66 million in FYE 2024 to approximately $7.84 million in FYE 2025. This growth was driven primarily by acquisitions of operating businesses in sectors characterized by durable demand, technical specialization, and supply chain importance. PMGC continues to focus on allocating capital into assets capable of generating sustainable cash flow and long-term compounding. Acquiring a Portfolio of Operating Businesses In FYE 2025, PMGC completed 3 acquisitions across precision manufacturing and industrial packaging. These businesses share core attributes: High technical barriers to entry; Mission-critical applications; Established blue chip customer bases; and Exposure to U.S. industrial and defense supply chain demand. Acquisitions Completed: Pacific Sun Packaging, Inc. — Acquired on July 7, 2025 Pacific Sun Packaging, Inc. (“Pacific Sun Packaging”) is a provider of specialized packaging solutions for semiconductor and data infrastructure components. Headquartered in San Clemente, California, Pacific Sun Packaging designs custom-engineered protective packaging for CPUs, memory modules, SSDs, fiber-optic transceivers, and other sensitive information technology (“IT”) hardware, serving over 300 commercial customers across North America’s semiconductor, data center and IT supply chains. AGA Precision Systems LLC — Acquired on July 18, 2025 AGA Precision Systems LLC (“AGA”) is a certified precision manufacturer serving aerospace and defense customers, including International Traffic in Arms Regulations (“ITAR”)-regulated work. AGA specializes in high-tolerance computer numerical control milling, turning, and machining of complex metals such as titanium and Inconel, and holds both ITAR registration and AS9100 certification. Indarg Engineering, Inc. (Asset Acquisition) — Acquired on October 26, 2025 Indarg Engineering, Inc. was a bolt-on acquisition completed through PMGC’s subsidiary, AGA. The acquisition expanded AGA’s machining capacity and operational scale to support growing demand from aerospace and industrial customers. Management believes the acquisitions listed above strengthen PMGC’s position in sectors where reliability and high switching costs support long-term customer retention and value creation. Positioned in Durable, High-Value Industries The acquisitions completed in FYE 2025 place PMGC squarely within two industrial verticals: precision manufacturing and specialty IT hardware packaging, where the Company believes structural demand drivers support continued growth into 2026 and beyond. Precision Manufacturing PMGC believes U.S. defense spending, aerospace production backlogs, and federal reshoring initiatives continue to drive demand for certified, domestic machine shops. Qualified domestic manufacturers holding both ITAR registration and AS9100D certification represent a narrow segment of the broader U.S. machining industry. As prime defense contractors and Tier 1 aerospace customers increasingly prioritize onshoring and supply chain security, demand for certified, U.S.-based precision shops continues to grow. The Company believes that once qualified as a supplier on a program, customer retention is reinforced by the rigorous requalification processes and first article inspection requirements associated with changing manufacturers. Specialty Packaging The continued buildout of data center infrastructure, driven by cloud computing, artificial intelligence, and enterprise IT refresh cycles, is generating increased demand for precision component-level packaging that protects high-value semiconductors, memory, and networking hardware. PMGC believes Pacific Sun Packaging’s established relationships with original equipment manufacturers, distributors, and data center operators position it to benefit from this investment cycle. Looking ahead to 2026, PMGC intends to pursue both organic and selective acquisitions that expand operational scale and deepen its presence in markets with favorable long-term fundamentals. Northstrive Biosciences: Advancing a Multi-Asset Biopharma Pipeline Northstrive Biosciences Inc. (“Northstrive Biosciences”), PMGC’s biopharmaceutical subsidiary, advanced multiple initiatives in the aggregate during FYE 2025 and early 2026, spanning clinical-stage development, preclinical research, AI-driven drug discovery, and commercial licensing. All programs focus on muscle preservation in the context of GLP-1 receptor agonist weight loss therapies, a rapidly growing therapeutic class. EL-22 — FDA Supports Path to Phase 2 IND Submission EL-22, Northstrive Bioscience’s lead asset, is a first-in-class engineered oral probiotic designed to preserve muscle mass in patients on GLP-1 weight loss treatments. Following a completed Phase 1 clinical trial in South Korea demonstrating favorable safety and tolerability, preliminary U.S. Food and Drug Administration (“FDA”) feedback indicated that Northstrive Biosciences’s nonclinical and Phase 1 data appear adequate to support initiation of a Phase 2 clinical trial in the USA. Northstrive Biosciences believes the FDA has provided a clear path forward for filing an Investigational New Drug application to conduct a Phase 2 trial evaluating EL-22 in combination with GLP-1 receptor agonists for obesity. Northstrive Biosciences is evaluating licensing, strategic partnerships, and direct development pathways for clinical advancement, subject to available financing. EL-32 — Preclinical Study Underway In March 2026, Northstrive Biosciences initiated a preclinical study for EL-32, a dual-action engineered probiotic candidate expressing both myostatin and activin-A antigens. This study uses a diet-induced obesity mouse model to evaluate muscle preservation and fat loss both as a standalone therapy and in combination with semaglutide. Dosing and observation are currently underway. Modulant Biosciences — Animal Health License Agreement Executed In February 2026, Northstrive Biosciences executed an exclusive, royalty-bearing license agreement with Modulant Biosciences LLC for the worldwide development and commercialization of EL-22 and EL-32 derived products in non-human animal health applications, including feed additives. Northstrive Biosciences retains all human therapeutic rights. Through this agreement, the parties aim to convert Northstrive Bioscience’s proprietary technology into a potential revenue-generating asset within the global animal health market. Yuva Biosciences — AI Drug Discovery Advances to Experimental Validation Northstrive’s AI Development Program with Yuva Biosciences, Inc. (“YuvaBio”) progressed to Phase III in December 2025, moving from computational screening to experimental validation of small-molecule candidates identified by YuvaBio’s MitoNova™ platform. This program targets compounds that may support mitochondrial health and muscle preservation in GLP-1-treated patients. YuvaBio has since deployed improved sixth-generation classifier models and Phase III results are currently expected in Q2 2026. Together, the above Northstrive Biosciences programs position it with a differentiated oral approach to muscle preservation, an area where existing therapies remain limited to injectable delivery. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact: [email protected]

NEWPORT BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months and six months ended June 30, 2025, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the company’s filings, as well as on the Company’s investor relations website. Management believes the Company is well-capitalized, with a strong balance sheet and a clearly defined business focus. Through its operating subsidiaries, the Company is advancing its strategic growth priorities and actively pursuing acquisitions of operating B2B businesses and assets with the potential to drive meaningful revenue growth and enhance shareholder value. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact: [email protected]

Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers. Adds cash flow positive revenue, enhances PMGC’s exposure to U.S. semiconductor and artificial intelligence (“AI”) infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. (“Pacific Sun”) a specialized custom IT packaging company based in San Clemente, California. About Pacific Sun Packaging Inc. Founded in 2011, Pacific Sun Packaging Inc. is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology (“IT”) hardware industries. The company designs and supplies custom-engineered protective packaging for delicate components such as central processing units (CPUs), memory modules (DIMMs and SO-DIMMs), solid state drives (SSDs), hard disk drives (HDDs), and fiber-optic transceivers, serving customers across the semiconductor, data center, and networking equipment supply chains. Pacific Sun’s solutions are built to meet the demanding durability, antistatic protection, and dimensional requirements of sensitive electronic parts during storage, shipping, and integration. Its products are widely used by original equipment manufacturers (OEMs), distributors, and contract manufacturers requiring scalable, reliable, and technically compliant packaging options. Known for its engineering agility, fulfillment reliability, and component-specific packaging expertise, the company operates a lean, cash-generative model from its base in San Clemente, California. In fiscal years 2023 and 2024, Pacific Sun generated combined revenue of $2,151,418. Strategic Rationale The acquisition of Pacific Sun marks the first completed transaction in PMGC’s broader acquisition strategy, which targets businesses with consistent earnings, strong fundamentals, and scalable platforms. Pacific Sun operates in a specialized and growing segment of the packaging industry, supported by long-standing customer relationships, high service reliability, and deep expertise in meeting the complex needs of the technology supply chain. The company’s ability to deliver tailored, component-specific solutions with speed and consistency has made it a trusted partner to electronics and IT hardware providers navigating increased demand and supply chain complexity. PMGC plans to work closely with Pacific Sun’s existing leadership to identify and execute growth initiatives, including the buildout of a dedicated sales function, targeted marketing investments, and operational enhancements. With the right capital and strategic support, Pacific Sun is well-positioned to expand its commercial footprint and serve a broader range of customers in the growing electronics and logistics ecosystem. “Pacific Sun Packaging represents everything we look for in a foundational operating platform: consistent profitability, customer loyalty, and strategic exposure to macro tailwinds,” said Graydon Bensler, Chief Executive Officer of PMGC Holdings Inc, managed through GB Capital Ltd. “As semiconductor, electronics manufacturing, and AI data centers increasingly move back onshore, and demand for servers, memory, and IT components continues to grow, we believe this business is well-positioned to scale with America’s advanced manufacturing revival, and we are excited to help meet that demand.” Industry Outlook The U.S. market for custom IT and electronics packaging is poised for multi-year growth. According to industry data: The North American electronics packaging market exceeded $8 billion in 2023.1 Demand is driven by the cloud, data center, and AI hardware boom, with memory modules and optical networking components requiring high-spec packaging solutions. The CHIPS and Science Act is incentivizing domestic production, increasing demand for U.S.-based packaging partners. E-commerce growth and stricter sustainability regulations are reshaping packaging needs—rewarding suppliers that offer recyclable, efficient, and customizable designs. PMGC acquired 100% of the issued and outstanding shares of Pacific Sun for $1,148,000 in cash, with an additional $250,000 earnout contingent on the company achieving $1,145,915 in revenue over the 12-month period following closing. About PMGC Holdings Inc. PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations Contact: [email protected] 1 North America Consumer Electronics Packaging Market Report – Industry Trends and Forecast to 2031 | Data Bridge Market Research

NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the company’s filings, as well as on the Company’s investor relations website. Management believes the Company is well-capitalized, with a strong balance sheet and a clearly defined business focus. Through its operating subsidiaries, the Company is advancing its strategic growth priorities and actively pursuing acquisitions of operating B2B businesses and assets with the potential to drive meaningful revenue growth and enhance shareholder value. Current Operating Subsidiaries: • NorthStrive Biosciences Inc. – A biopharmaceutical company focused on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, leverages an engineered probiotic approach to address a pressing issue in the obesity market by preserving muscle in patients undergoing weight loss treatments, including GLP-1 receptor agonists. For more information, visit northstrivebio.com. • PMGC Research Inc. – A research and development subsidiary that utilizes Canadian research grants and partners with leading Canadian universities to accelerate scientific discovery and transform cutting-edge technologies into commercially viable products. • PMGC Capital LLC – A multi-strategy investment firm focused on direct investments, strategic lending, and the acquisition of undervalued companies and assets across diverse markets. Its mission is to identify and seize high-potential opportunities to deliver sustainable growth and maximize returns on capital. • Pending Acquisition – On April 16, 2025, the Company announced the signing of a non-binding Letter of Intent (“LOI”) to acquire a U.S.-based, cash-flow-positive information technology (“IT”) custom packaging company. About PMGC Holdings Inc. PMGC is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the SEC, including the “Risk Factors” section of the Company’s Annual Report for the year ended December 31, 2024, filed with the SEC on March 26, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. IR Contact:[email protected]